Profile data is unavailable for this security.
About the company
Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
- Revenue in USD (TTM)73.00k
- Net income in USD-13.99m
- Incorporated2012
- Employees12.00
- LocationOrganovo Holdings IncSuite 100, 11555 Sorrento Valley RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 224-1000
- Fax+1 (302) 636-5454
- Websitehttps://organovo.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Windtree Therapeutics Inc | 0.00 | -11.38m | 4.92m | 15.00 | -- | 0.0954 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
| Weed Inc | 0.00 | 57.30k | 4.93m | 2.00 | 78.24 | 655.18 | 56.97 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Check Cap Ltd | 0.00 | -17.57m | 5.07m | 85.00 | -- | 0.2142 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Aptevo Therapeutics Inc | 0.00 | -25.25m | 5.09m | 40.00 | -- | 0.2513 | -- | -- | -46.21 | -45.63 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -115.20 | -47.16 | -160.28 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.47m | 5.34m | 1.00 | -- | 0.5641 | -- | -- | -4.26 | 1.27 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -103.82 | -72.70 | -150.23 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Genprex Inc | 0.00 | -26.14m | 5.41m | 26.00 | -- | 1.23 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Organovo Holdings Inc | 73.00k | -13.99m | 5.55m | 12.00 | -- | 0.7797 | -- | 76.07 | -1.39 | -1.39 | 0.0069 | 0.4635 | 0.006 | -- | 0.7411 | 3,650.00 | -115.47 | -54.25 | -136.97 | -58.42 | 50.68 | -- | -19,160.27 | -1,890.16 | 3.38 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
| Exicure Inc | 500.00k | -8.17m | 5.57m | 5.00 | -- | 3.45 | -- | 11.14 | -4.72 | -4.72 | 0.2889 | 0.9323 | 0.0354 | -- | -- | 83,333.34 | -57.87 | -41.52 | -69.90 | -55.78 | -- | -- | -1,634.40 | -290.95 | -- | -- | 0.3827 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Carmell Corp | 12.32k | -15.97m | 5.83m | 9.00 | -- | -- | -- | 473.43 | -1.53 | -1.44 | 0.0006 | -0.0656 | -- | -- | -- | 1,368.89 | -- | -- | -- | -- | 58.73 | -- | -129,263.60 | -- | 0.6901 | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| Eterna Therapeutics Inc | 162.00k | -23.94m | 5.84m | 8.00 | -- | -- | -- | 36.07 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Enzon Pharmaceuticals Inc | 26.00k | 314.00k | 5.86m | 0.00 | 18.68 | 1.93 | -- | 225.50 | 0.0042 | 0.0042 | 0.0004 | 0.6277 | 0.0006 | -- | -- | -- | 3.39 | -0.8654 | 3.42 | -0.8851 | -- | -- | 6,111.54 | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| BioNexus Gene Lab Corp | 9.18m | -2.21m | 5.93m | 30.00 | -- | 0.6108 | -- | 0.6457 | -0.1108 | -0.1108 | 0.5807 | 0.5403 | 0.9647 | 7.19 | 5.77 | -- | -23.17 | -3.83 | -27.98 | -5.02 | 13.88 | 14.55 | -24.02 | -3.04 | 4.87 | -118.92 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Clearmind Medicine Inc | 0.00 | -8.44m | 6.21m | -- | -- | 1.75 | -- | -- | -12.73 | -12.73 | 0.00 | 0.8728 | 0.00 | -- | -- | -- | -133.31 | -218.20 | -266.82 | -488.96 | -- | -- | -- | -- | -- | -2.60 | 0.0172 | -- | -- | -- | -25.03 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 929.00k | 6.05% |
| Prescott Group Capital Management LLCas of 30 Sep 2024 | 414.04k | 2.70% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 353.61k | 2.30% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 142.21k | 0.93% |
| Geode Capital Management LLCas of 30 Jun 2024 | 110.36k | 0.72% |
| Citadel Securities LLCas of 30 Jun 2024 | 79.26k | 0.52% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 63.39k | 0.41% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 38.78k | 0.25% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 29.78k | 0.19% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 27.83k | 0.18% |
